1 1684 149 DRUG-TOLERANT CANCER CELLS SHOW REDUCED TUMOR-INITIATING CAPACITY: DEPLETION OF CD44 CELLS AND EVIDENCE FOR EPIGENETIC MECHANISMS. CANCER STEM CELLS (CSCS) POSSESS HIGH TUMOR-INITIATING CAPACITY AND HAVE BEEN REPORTED TO BE RESISTANT TO THERAPEUTICS. VICE VERSA, THERAPY-RESISTANT CANCER CELLS SEEM TO MANIFEST CSC PHENOTYPES AND PROPERTIES. IT HAS BEEN GENERALLY ASSUMED THAT DRUG-RESISTANT CANCER CELLS MAY ALL BE CSCS ALTHOUGH THE GENERALITY OF THIS ASSUMPTION IS UNKNOWN. HERE, WE CHRONICALLY TREATED DU145 PROSTATE CANCER CELLS WITH ETOPOSIDE, PACLITAXEL AND SOME EXPERIMENTAL DRUGS (I.E., STAUROSPORINE AND 2 PACLITAXEL ANALOGS), WHICH LED TO POPULATIONS OF DRUG-TOLERANT CELLS (DTCS). SURPRISINGLY, THESE DTCS, WHEN IMPLANTED EITHER SUBCUTANEOUSLY OR ORTHOTOPICALLY INTO NOD/SCID MICE, EXHIBITED MUCH REDUCED TUMORIGENICITY OR WERE EVEN NON-TUMORIGENIC. DRUG-TOLERANT DLD1 COLON CANCER CELLS SELECTED BY A SIMILAR CHRONIC SELECTION PROTOCOL ALSO DISPLAYED REDUCED TUMORIGENICITY WHEREAS DRUG-TOLERANT UC14 BLADDER CANCER CELLS DEMONSTRATED EITHER INCREASED OR DECREASED TUMOR-REGENERATING CAPACITY. DRUG-TOLERANT DU145 CELLS DEMONSTRATED LOW PROLIFERATIVE AND CLONOGENIC POTENTIAL AND WERE VIRTUALLY DEVOID OF CD44(+) CELLS. PROSPECTIVE KNOCKDOWN OF CD44 IN DU145 CELLS INHIBITED CELL PROLIFERATION AND TUMOR REGENERATION, WHEREAS RESTORATION OF CD44 EXPRESSION IN DRUG-TOLERANT DU145 CELLS INCREASED CELL PROLIFERATION AND PARTIALLY INCREASED TUMORIGENICITY. INTERESTINGLY, DRUG-TOLERANT DU145 CELLS SHOWED BOTH INCREASES AND DECREASES IN MANY "STEMNESS" GENES. FINALLY, EVIDENCE WAS PROVIDED THAT CHRONIC DRUG EXPOSURE GENERATED DTCS VIA EPIGENETIC MECHANISMS INVOLVING MOLECULES SUCH AS CD44 AND KDM5A. OUR RESULTS THUS REVEAL THAT 1) NOT ALL DTCS ARE NECESSARILY CSCS; 2) CONVENTIONAL CHEMOTHERAPEUTIC DRUGS SUCH AS TAXOL AND ETOPOSIDE MAY DIRECTLY TARGET CD44(+) TUMOR-INITIATING CELLS; AND 3) DTCS GENERATED VIA CHRONIC DRUG SELECTION INVOLVE EPIGENETIC MECHANISMS. 2011 2 5785 33 SPONTANEOUS NEOPLASTIC TRANSFORMATION OF WB-F344 RAT LIVER EPITHELIAL CELLS. SEVERAL STUDIES HAVE SHOWN THAT CULTURED RAT LIVER EPITHELIAL CELLS TRANSFORM SPONTANEOUSLY AFTER CHRONIC MAINTENANCE IN A CONFLUENT STATE IN VITRO. IN THE PRESENT STUDY, MULTIPLE INDEPENDENT LINEAGES OF LOW-PASSAGE WB-F344 RAT LIVER EPITHELIAL STEM-LIKE CELLS WERE INITIATED AND SUBJECTED IN PARALLEL TO SELECTION FOR SPONTANEOUS TRANSFORMATION TO DETERMINE WHETHER SPONTANEOUS ACQUISITION OF TUMORIGENICITY WAS THE RESULT OF EVENTS (GENETIC OR EPIGENETIC) THAT OCCURRED INDEPENDENTLY AND STOCHASTICALLY, OR REFLECTED THE EXPRESSION OF A PRE-EXISTING ALTERATION WITHIN THE PARENTAL WB-F344 CELL LINE. TEMPORAL ANALYSIS OF THE SPONTANEOUS ACQUISITION OF TUMORIGENICITY BY WB-F344 CELLS DEMONSTRATED LINEAGE-SPECIFIC DIFFERENCES IN THE TIME OF FIRST EXPRESSION OF THE TUMORIGENIC PHENOTYPE, FREQUENCIES AND LATENCIES OF TUMOR FORMATION, AND TUMOR DIFFERENTIATIONS. ALTHOUGH SPONTANEOUSLY TRANSFORMED WB-F344 CELLS PRODUCED DIVERSE TUMOR TYPES (INCLUDING HEPATOCELLULAR CARCINOMAS, CHOLANGIOCARCINOMAS, HEPATOBLASTOMAS, AND OSTEOGENIC SARCOMAS), INDIVIDUAL LINEAGES YIELDED TUMORS WITH CONSISTENT AND SPECIFIC PATTERNS OF DIFFERENTIATION. THESE RESULTS PROVIDE SUBSTANTIAL EVIDENCE THAT THE STOCHASTIC ACCUMULATION OF INDEPENDENT TRANSFORMING EVENTS DURING THE SELECTION REGIMEN IN VITRO WERE RESPONSIBLE FOR SPONTANEOUS NEOPLASTIC TRANSFORMATION OF WB-F344 CELLS. FURTHERMORE, CELL LINEAGE COMMITMENT TO A SPECIFIC DIFFERENTIATION PROGRAM WAS STABLE WITH TIME IN CULTURE AND WITH SITE OF TRANSPLANTATION. THIS IS THE FIRST REPORT OF A COHORT OF RELATED, BUT INDEPENDENT, RAT LIVER EPITHELIAL CELL LINES THAT COLLECTIVELY PRODUCE A SPECTRUM OF TUMOR TYPES BUT INDIVIDUALLY REPRODUCE A SPECIFIC TUMOR TYPE. THESE CELL LINES WILL PROVIDE VALUABLE REAGENTS FOR INVESTIGATION OF THE MOLECULAR MECHANISMS INVOLVED IN THE DIFFERENTIATION OF HEPATIC STEM-LIKE CELLS AND FOR EXAMINATION OF POTENTIAL CAUSAL RELATIONSHIPS IN SPONTANEOUSLY TRANSFORMED RAT LIVER EPITHELIAL CELL LINES BETWEEN MOLECULAR/CELLULAR ALTERATIONS AND THE ABILITY TO PRODUCE TUMORS IN SYNGENEIC ANIMALS. 1998 3 3195 41 HDAC INHIBITORS AUGMENTED CELL MIGRATION AND METASTASIS THROUGH INDUCTION OF PKCS LEADING TO IDENTIFICATION OF LOW TOXICITY MODALITIES FOR COMBINATION CANCER THERAPY. PURPOSE: HISTONE DEACETYLASE INHIBITORS (HDACI) ARE ACTIVELY EXPLORED AS NEW-GENERATION EPIGENETIC DRUGS BUT HAVE LOW EFFICACY IN CANCER MONOTHERAPY. TO REVEAL NEW MECHANISM FOR COMBINATION THERAPY, WE SHOW THAT HDACI INDUCE CELL DEATH BUT SIMULTANEOUSLY ACTIVATE TUMOR-PROGRESSIVE GENES TO RUIN THERAPEUTIC EFFICACY. COMBINED TREATMENTS TO TARGET TUMORIGENESIS AND HDACI-ACTIVATED METASTASIS WITH LOW TOXIC MODALITIES COULD DEVELOP NEW STRATEGIES FOR LONG-TERM CANCER THERAPY. EXPERIMENTAL DESIGN: BECAUSE METASTASIS IS THE MAJOR CAUSE OF CANCER MORTALITY, WE MEASURED CELL MIGRATION ACTIVITY AND PROFILED METASTASIS-RELATED GENE EXPRESSIONS IN HDACI-TREATED CANCER CELLS. WE DEVELOPED LOW TOXIC COMBINATION MODALITIES TARGETING TUMORIGENESIS AND HDACI-ACTIVATED METASTASIS FOR PRECLINICAL THERAPIES IN MICE. RESULTS: WE SHOWED THAT CELL MIGRATION ACTIVITY WAS DRAMATICALLY AND DOSE DEPENDENTLY ENHANCED BY VARIOUS CLASSES OF HDACI TREATMENTS IN 13 OF 30 EXAMINED HUMAN BREAST, GASTRIC, LIVER, AND LUNG CANCER CELL LINES. TUMOR METASTASIS WAS ALSO ENHANCED IN HDACI-TREATED MICE. HDACI TREATMENTS ACTIVATED MULTIPLE PKCS AND DOWNSTREAM SUBSTRATES ALONG WITH UPREGULATED PROAPOPTOTIC P21. FOR TARGETING TUMORIGENESIS AND METASTASIS WITH IMMEDIATE CLINICAL IMPACT, WE SHOWED THAT NEW MODALITIES OF HDACI COMBINED DRUGS WITH PKC INHIBITORY AGENT, CURCUMIN OR TAMOXIFEN, NOT ONLY SUPPRESSED HDACI-ACTIVATED TUMOR PROGRESSIVE PROTEINS AND CELL MIGRATION IN VITRO BUT ALSO INHIBITED TUMOR GROWTH AND METASTASIS IN VIVO. CONCLUSION: TREATMENTS OF DIFFERENT STRUCTURAL CLASSES OF HDACI SIMULTANEOUSLY INDUCED CELL DEATH AND PROMOTED CELL MIGRATION AND METASTASIS IN MULTIPLE CANCER CELL TYPES. SUPPRESSION OF HDACI-INDUCED PKCS LEADS TO DEVELOPMENT OF LOW TOXIC AND LONG-TERM THERAPEUTIC STRATEGIES TO POTENTIALLY TREAT CANCER AS A CHRONIC DISEASE. 2012 4 306 34 AKT TARGETING AS A STRATEGY TO BOOST CHEMOTHERAPY EFFICACY IN NON-SMALL CELL LUNG CANCER THROUGH METABOLISM SUPPRESSION. METABOLIC REPROGRAMMING IS A HALLMARK OF CANCER DEVELOPMENT, MEDIATED BY GENETIC AND EPIGENETIC ALTERATIONS THAT MAY BE PHARMACOLOGICALLY TARGETED. AMONG ONCOGENES, THE KINASE AKT IS COMMONLY OVEREXPRESSED IN TUMORS AND FAVORS GLYCOLYSIS, PROVIDING A RATIONALE FOR USING AKT INHIBITORS. HERE, WE ADDRESSED THE QUESTION OF WHETHER AND HOW INHIBITING AKT ACTIVITY COULD IMPROVE THERAPY OF NON-SMALL CELL LUNG CANCER (NSCLC) THAT REPRESENTS MORE THAN 80% OF ALL LUNG CANCER CASES. FIRST, WE DEMONSTRATED THAT AKT INHIBITORS INTERACTED SYNERGISTICALLY WITH MICROTUBULE-TARGETING AGENTS (MTAS) AND SPECIFICALLY IN CANCER CELL LINES, INCLUDING THOSE RESISTANT TO CHEMOTHERAPY AGENTS AND ANTI-EGFR TARGETED THERAPIES. IN VIVO, WE FURTHER REVEALED THAT THE CHRONIC ADMINISTRATION OF LOW-DOSES OF PACLITAXEL - I.E. METRONOMIC SCHEDULING - AND THE ANTI-AKT PERIFOSINE WAS THE MOST EFFICIENT AND THE BEST TOLERATED TREATMENT AGAINST NSCLC. REGARDING DRUG MECHANISM OF ACTION, PERIFOSINE POTENTIATED THE PRO-APOPTOTIC EFFECTS OF PACLITAXEL, INDEPENDENTLY OF CELL CYCLE ARREST, AND COMBINING PACLITAXEL/PERIFOSINE RESULTED IN A SUSTAINED SUPPRESSION OF GLYCOLYTIC AND MITOCHONDRIAL METABOLISM. THIS STUDY POINTS OUT THAT TARGETING CANCER CELL BIOENERGETICS MAY REPRESENT A NOVEL THERAPEUTIC AVENUE IN NSCLC, AND PROVIDES A STRONG FOUNDATION FOR FUTURE CLINICAL TRIALS OF METRONOMIC MTAS COMBINED WITH AKT INHIBITORS. 2017 5 402 35 ANALYSIS OF APOPTOSOME DYSREGULATION IN PANCREATIC CANCER AND OF ITS ROLE IN CHEMORESISTANCE. THE APOPTOSOME IS A MULTIPROTEIN COMPLEX MEDIATING THE MITOCHONDRIAL PATHWAY OF CELL DEATH. ITS IMPORTANCE DURING DEVELOPMENT HAS BEEN CLEARLY DEMONSTRATED BY KNOCKING OUT KEY GENES IN MOUSE. APAF1 IS THE CORE PROTEIN OF THE APOPTOSOME AND ITS DOSAGE IS ALSO CRITICAL IN VARIOUS CANCER TYPES, I.E., MELANOMA, GERM LINE TUMOR, GASTROINTESTINAL CANCER AND B-TYPE CHRONIC LYMPHOCYTIC LEUKEMIA. THIS IS GENERALLY DUE TO INACTIVATION OF THE APAF1 LOCUS BY EPIGENETIC PHENOMENA OR BY ACTIVITY OF PROMOTER REGULATORS. WE INVESTIGATED THE PUTATIVE ROLES OF THE APOPTOSOME IN PANCREATIC DUCTAL ADENOCARCINOMA (PDAC). WE FOUND THAT BOTH APAF1 MRNA AND PROTEIN ARE DYSREGULATED IN HUMAN PDAC SAMPLES. SIMILARLY, SEVERAL PDAC CELL LINES EXHIBITED VARIABLE LEVELS OF BOTH APAF1 PROTEIN AND MRNA. THE RESPONSE TO CELL DEATH INDUCTION AND ITS BIOCHEMICAL FEATURES WERE ASSESSED BY TREATMENT OF EACH LINE WITH COMMONLY USED CHEMOTHERAPEUTIC AGENTS. WE FOUND THAT THE APOPTOSOME PATHWAY WAS NOT FUNCTIONAL IN MOST CELL LINES UPON CYTOCHROME C RELEASE FROM MITOCHONDRIA. IN ADDITION, WE RESTORED APAF1 AND CASPASE-9 DOSAGE IN PANC-1 CELLS, WHERE THE APOPTOSOME IS DOWNREGULATED, BY OVEREXPRESSING THE MURINE CDNA OF THE TWO MOLECULES, AND WE IMPROVED THE DEATH RESPONSE TO CHEMOTHERAPEUTIC AGENTS. 2007 6 5491 40 REVIEW ARTICLE: INFLAMMATION-RELATED PROMOTION OF GASTROINTESTINAL CARCINOGENESIS--A PERIGENETIC PATHWAY. CHRONIC INFLAMMATION HAS BEEN REPORTED TO ACCELERATE NEOPLASMAS IN GASTROINTESTINAL TRACT. CERTAIN BACTERIA INCLUDING HELICOBACTER PYLORI DIRECTLY INTERACT WITH HOST CELLS, INDUCE PROINFLAMMATORY CYTOKINES AND STIMULATE PRODUCTION OF FREE RADICALS. FREE RADICALS CAUSE MUTATIONS IN TARGET CELLS SO THAT NEOPLASTIC CLONES ARE ESTABLISHED. ACCUMULATION OF SUCH GENETIC ALTERATIONS MAY CAUSE MALIGNANT TRANSFORMATION OF SOME ESTABLISHED CLONES. IN ADDITION, INFLAMMATORY ALTERATIONS MAY PROMOTE GROWTH, EXPANSION AND INVASION OF GASTROINTESTINAL EPITHELIAL CELLS. THE LATTER CHANGES CAUSED BY INFLAMMATION MAY OCCUR EVEN WITHOUT FURTHER GENETIC MUTATIONS OR EPIGENETIC ALTERATIONS, AND THEREFORE MAY BE CATEGORIZED AS 'PERIGENETIC ALTERATIONS' OF NEOPLASTIC CELLS. FOR AN EXAMPLE, TUMOUR NECROSIS FACTOR ALPHA (TNF-ALPHA) PLAYS PIVOTAL ROLES NOT ONLY IN THE REDUCTION BUT ALSO IN THE GROWTH, INVASION AND METASTASES OF CERTAIN NEOPLASMAS. OUR STUDIES SHOW THAT TNF-ALPHA INCREASES INTRACELLULAR RADICAL PRODUCTION, DEGRADATES E-CADHERIN / BETA-CATENIN COMPLEX AND PROMOTES DISPERSION AND MIGRATION IN EPITHELIAL CELLS TRANSFORMED WITH AN ACTIVATED SRC ONCOGENE (V-SRC). THESE DATA INDICATE THAT AN INFLAMMATORY CYTOKINE INDUCES THE MALIGNANT POTENTIAL OF SRC-ACTIVATED NEOPLASTIC CELLS. INTERESTINGLY, TNF-ALPHA ALSO INDUCED THESE PHENOTYPIC CHANGES IN NONMUTATED CELLS WHOSE C-SRC WAS ACTIVATED BY TGF-ALPHA, SUGGESTING THAT THE INVASIVE PROPERTIES OF THE CELL WERE NOT NECESSARILY RELATED TO GENE MUTATION. FURTHERMORE, CERTAIN RADICAL SCAVENGERS SUPPRESSED THE INVASIVE PHENOTYPE OF THE CELLS. THESE RESULTS INDICATE THAT PERIGENETIC ALTERATIONS ARE AN IMPORTANT TARGET OF PHARMACOLOGICAL INTERVENTION OF CARCINOGENESIS. 2003 7 194 34 ACETYLSHIKONIN SUPPRESSES INVASION OF PORPHYROMONAS GINGIVALIS?INFECTED YD10B ORAL CANCER CELLS BY MODULATING THE INTERLEUKIN-8/MATRIX METALLOPROTEINASE AXIS. THE DEVELOPMENT OF PHARMACEUTICAL AGENTS POSSESSING ANTI?INVASIVE AND ANTI?METASTATIC ABILITIES, AS WELL AS APOPTOTIC ACTIVITY, IS IMPORTANT IN DECREASING THE INCIDENCE AND RECURRENCE OF ORAL CANCER. CANCER CELLS ARE KNOWN TO ACQUIRE INVASIVENESS NOT ONLY THROUGH EPIGENETIC CHANGES, BUT ALSO FROM INFLAMMATORY STIMULI WITHIN THE TUMOR MICROENVIRONMENT. ACCORDINGLY, THE IDENTIFICATION OF AGENTS THAT CAN SUPPRESS THE INFLAMMATION?PROMOTED INVASIVENESS OF CANCER CELLS MAY BE IMPORTANT IN TREATING CANCER AND IMPROVING THE PROGNOSIS OF PATIENTS WITH CANCER. ACETYLSHIKONIN, A FLAVONOID WITH ANTI?INFLAMMATORY ACTIVITY, INHIBITS PROLIFERATION AND INDUCES APOPTOSIS OF ORAL CANCER CELLS. IN THE PRESENT STUDY, THE ANTI?INVASIVE EFFECT OF ACETYLSHIKONIN ON YD10B ORAL CANCER CELLS INFECTED WITH PORPHYROMONAS GINGIVALIS, A MAJOR PATHOGEN OF CHRONIC PERIODONTITIS, AND THE MECHANISMS INVOLVED WERE INVESTIGATED. FIRSTLY, WE EXAMINED WHETHER P. GINGIVALIS INFECTION INCREASED THE INVASIVENESS OF YD10B CELLS. RESULTS SUGGESTED THAT YD10B ORAL CANCER CELLS BECOME MORE AGGRESSIVE WHEN THEY ARE INFECTED WITH P. GINGIVALIS. SECONDLY, ACETYLSHIKONIN SIGNIFICANTLY INHIBITED THE INVASION OF P. GINGIVALIS?INFECTED YD10B CELLS BY SUPPRESSING IL?8 RELEASE AND IL?8?DEPENDENT MMP RELEASE. THESE DATA SUGGEST THAT ACETYLSHIKONIN MAY BE A USEFUL PREVENTIVE AND THERAPEUTIC CANDIDATE FOR ORAL CANCER THAT IS CHRONICALLY INFECTED WITH PERIODONTAL PATHOGENS. 2018 8 5292 31 PROSTATIC INFLAMMATION ENHANCES BASAL-TO-LUMINAL DIFFERENTIATION AND ACCELERATES INITIATION OF PROSTATE CANCER WITH A BASAL CELL ORIGIN. CHRONIC INFLAMMATION HAS BEEN SHOWN TO PROMOTE THE INITIATION AND PROGRESSION OF DIVERSE MALIGNANCIES BY INDUCING GENETIC AND EPIGENETIC ALTERATIONS. IN THIS STUDY, WE INVESTIGATE AN ALTERNATIVE MECHANISM THROUGH WHICH INFLAMMATION PROMOTES THE INITIATION OF PROSTATE CANCER. ADULT MURINE PROSTATE EPITHELIA ARE COMPOSED PREDOMINANTLY OF BASAL AND LUMINAL CELLS. PREVIOUS STUDIES REVEALED THAT THE TWO LINEAGES ARE LARGELY SELF-SUSTAINED WHEN RESIDING IN THEIR NATIVE MICROENVIRONMENT. TO INTERROGATE WHETHER TISSUE INFLAMMATION ALTERS THE DIFFERENTIATION PROGRAM OF BASAL CELLS, WE CONDUCTED LINEAGE TRACING OF BASAL CELLS USING A K14-CREER;MTMG MODEL IN CONCERT WITH A MURINE MODEL OF PROSTATITIS INDUCED BY INFECTION FROM THE UROPATHOGENIC BACTERIA CP9. WE SHOW THAT ACUTE PROSTATITIS CAUSES TISSUE DAMAGE AND CREATES A TISSUE MICROENVIRONMENT THAT INDUCES THE DIFFERENTIATION OF BASAL CELLS INTO LUMINAL CELLS, AN ALTERATION THAT RARELY OCCURS UNDER NORMAL PHYSIOLOGICAL CONDITIONS. PREVIOUSLY WE SHOWED THAT A MOUSE MODEL WITH PROSTATE BASAL CELL-SPECIFIC DELETION OF PHOSPHATASE AND TENSIN HOMOLOG (K14-CREER;PTEN(FL/FL)) DEVELOPS PROSTATE CANCER WITH A LONG LATENCY, BECAUSE DISEASE INITIATION IN THIS MODEL REQUIRES AND IS LIMITED BY THE DIFFERENTIATION OF TRANSFORMATION-RESISTANT BASAL CELLS INTO TRANSFORMATION-COMPETENT LUMINAL CELLS. HERE, WE SHOW THAT CP9-INDUCED PROSTATITIS SIGNIFICANTLY ACCELERATES THE INITIATION OF PROSTATIC INTRAEPITHELIAL NEOPLASIA IN THIS MODEL. OUR RESULTS DEMONSTRATE THAT INFLAMMATION RESULTS IN A TISSUE MICROENVIRONMENT THAT ALTERS THE NORMAL PROSTATE EPITHELIAL CELL DIFFERENTIATION PROGRAM AND THAT THROUGH THIS CELLULAR PROCESS INFLAMMATION ACCELERATES THE INITIATION OF PROSTATE CANCER WITH A BASAL CELL ORIGIN. 2014 9 2927 39 GENERATION OF HUMAN CORTICAL NEURONS FROM A NEW IMMORTAL FETAL NEURAL STEM CELL LINE. ISOLATION AND EXPANSION OF NEURAL STEM CELLS (NSCS) OF HUMAN ORIGIN ARE CRUCIAL FOR SUCCESSFUL DEVELOPMENT OF CELL THERAPY APPROACHES IN NEURODEGENERATIVE DISEASES. DIFFERENT EPIGENETIC AND GENETIC IMMORTALIZATION STRATEGIES HAVE BEEN ESTABLISHED FOR LONG-TERM MAINTENANCE AND EXPANSION OF THESE CELLS IN VITRO. HERE WE REPORT THE GENERATION OF A NEW, CLONAL NSC (HC-NSC) LINE, DERIVED FROM HUMAN FETAL CORTICAL TISSUE, BASED ON V-MYC IMMORTALIZATION. USING IMMUNOCYTOCHEMISTRY, WE SHOW THAT THESE CELLS RETAIN THE CHARACTERISTICS OF NSCS AFTER MORE THAN 50 PASSAGES. UNDER PROLIFERATION CONDITIONS, WHEN SUPPLEMENTED WITH EPIDERMAL AND BASIC FIBROBLAST GROWTH FACTORS, THE HC-NSCS EXPRESSED NEURAL STEM/PROGENITOR CELL MARKERS LIKE NESTIN, VIMENTIN AND SOX2. WHEN GROWTH FACTORS WERE WITHDRAWN, PROLIFERATION AND EXPRESSION OF V-MYC AND TELOMERASE WERE DRAMATICALLY REDUCED, AND THE HC-NSCS DIFFERENTIATED INTO GLIA AND NEURONS (MOSTLY GLUTAMATERGIC AND GABAERGIC, AS WELL AS TYROSINE HYDROXYLASE-POSITIVE, PRESUMABLY DOPAMINERGIC NEURONS). RT-PCR ANALYSIS SHOWED THAT THE HC-NSCS RETAINED EXPRESSION OF PAX6, EMX2 AND NEUROGENIN2, WHICH ARE GENES ASSOCIATED WITH REGIONALIZATION AND CELL COMMITMENT IN CORTICAL PRECURSORS DURING BRAIN DEVELOPMENT. OUR DATA INDICATE THAT THIS HC-NSC LINE COULD BE USEFUL FOR EXPLORING THE POTENTIAL OF HUMAN NSCS TO REPLACE DEAD OR DAMAGED CORTICAL CELLS IN ANIMAL MODELS OF ACUTE AND CHRONIC NEURODEGENERATIVE DISEASES. TAKING ADVANTAGE OF ITS CLONALITY AND HOMOGENEITY, THIS CELL LINE WILL ALSO BE A VALUABLE EXPERIMENTAL TOOL TO STUDY THE REGULATORY ROLE OF INTRINSIC AND EXTRINSIC FACTORS IN HUMAN NSC BIOLOGY. 2007 10 3660 40 INDUCTION OF HEPATIC DIFFERENTIATION OF MOUSE BONE MARROW STROMAL STEM CELLS BY THE HISTONE DEACETYLASE INHIBITOR VPA. BONE MARROW STROMAL STEM CELLS (BMSSCS) MAY HAVE POTENTIAL TO DIFFERENTIATE IN VITRO AND IN VIVO INTO HEPATOCYTES. HERE, WE INVESTIGATED THE EFFECTS OF VALPROIC ACID (VPA) INVOLVED IN EPIGENETIC MODIFICATION, A DIRECT INHIBITOR OF HISTONE DEACETYLASE, ON HEPATIC DIFFERENTIATION OF MOUSE BMSSCS. FOLLOWING THE TREATMENT OF 2.5 MM VPA FOR 72 HRS, THE IN VITRO EXPANDED, HIGHLY PURIFIED AND FUNCTIONALLY ACTIVE MOUSE BMSSCS FROM BONE MARROW WERE EITHER EXPOSED TO SOME WELL-DEFINED CYTOKINES AND GROWTH FACTORS IN A SEQUENTIAL WAY (FIBROBLAST GROWTH FACTOR-4 [FGF-4], FOLLOWED BY HGF, AND HGF + OSM + ITS + DEXAMETHASONE, RESEMBLING THE ORDER OF SECRETION DURING LIVER EMBRYOGENESIS) OR TRANSPLANTED (CAUDAL VEIN) IN MICE SUBMITTED TO A PROTOCOL OF CHRONIC INJURY (CHRONIC I.P. INJECTION OF CCL4). ADDITIONAL EXPOSURE OF THE CELLS TO VPA CONSIDERABLY IMPROVED THE IN VITRO DIFFERENTIATION, AS DEMONSTRATED BY A MORE HOMOGENEOUS CELL POPULATION EXHIBITED EPITHELIAL MORPHOLOGY, INCREASING EXPRESSION OF HEPATIC SPECIAL GENES AND ENHANCED HEPATIC FUNCTIONS. FURTHER MORE, IN VIVO RESULTS INDICATE THAT THE PRE-TREATMENT OF VPA SIGNIFICANTLY INCREASED THE HOMING EFFICIENCY OF BMSSCS TO THE SITE OF LIVER INJURY AND, ADDITIONALLY, FOR SUPPORTING HEPATIC DIFFERENTIATION AS WELL AS IN VITRO. WE HAVE DEMONSTRATED THE USEFULNESS OF VPA IN THE TRANSDIFFERENTIATION OF BMSSCS INTO HEPATOCYTES BOTH IN VITRO AND IN VIVO, AND REGULATION OF FIBROBLAST GROWTH FACTOR RECEPTORS (FGFRS) AND C-MET GENE EXPRESSION THROUGH POST-TRANSLATIONAL MODIFICATION OF CORE HISTONES MIGHT BE THE PRIMARY INITIATING EVENT FOR THESE EFFECTS. THIS MODE COULD BE HELPFUL FOR LIVER ENGINEERING AND CLINICAL THERAPY. 2009 11 19 43 5-AZACYTYDINE AND RESVERATROL REVERSE SENESCENCE AND AGEING OF ADIPOSE STEM CELLS VIA MODULATION OF MITOCHONDRIAL DYNAMICS AND AUTOPHAGY. OBESITY AND ENDOCRINE DISORDERS HAVE BECOME PREVALENT ISSUES IN THE FIELD OF BOTH HUMAN AND VETERINARY MEDICINE. EQUINE METABOLIC SYNDROME IS A COMPLEX DISORDER INVOLVING ALTERNATION IN METABOLISM AND CHRONIC SYSTEMIC INFLAMMATION. IT HAS BEEN SHOWN THAT UNFAVOURABLE MICROENVIRONMENT OF INFLAMED ADIPOSE TISSUE NEGATIVELY AFFECTS ADIPOSE STEM CELL POPULATION (ASC) RESIDING WITHIN, MARKEDLY LIMITING THEIR THERAPEUTIC POTENTIAL. ASCS(EMS) ARE CHARACTERIZED BY INCREASED SENESCENCE APOPTOSIS, EXCESSIVE ACCUMULATION OF REACTIVE OXYGEN SPECIES (ROS), MITOCHONDRIA DETERIORATION AND "AUTOPHAGIC FLUX." THE AIM OF THE PRESENT STUDY WAS TO EVALUATE WHETHER TREATMENT OF ASCS(EMS) WITH A COMBINATION OF 5-AZACYTYDINE (AZA) AND RESVERATROL (RES) WOULD REVERSE AGED PHENOTYPE OF THESE CELLS. FOR THIS REASON, WE PERFORMED THE FOLLOWING ANALYZES: MOLECULAR BIOLOGY (RT-PCR), MICROSCOPIC (IMMUNOFLUORESCENCE, TEM) AND FLOW CYTOMETRY (JC-1, ROS, KI67). WE EVALUATED THE MITOCHONDRIAL STATUS, DYNAMICS AND CLEARANCE AS WELL AS AUTOPHAGIC PATHWAYS. FURTHERMORE, WE INVESTIGATED EPIGENETIC ALTERNATIONS IN TREATED CELLS BY MEASURING THE EXPRESSION OF TET GENES AND ANALYSIS OF DNA METHYLATION STATUS. WE HAVE DEMONSTRATED THAT AZA/RES TREATMENT OF ASCS(EMS) IS ABLE TO REJUVENATE THESE CELLS BY MODULATING MITOCHONDRIAL DYNAMICS, IN PARTICULAR BY PROMOTING MITOCHONDRIAL FUSION OVER FISSION. AFTER AZA/RES TREATMENT, ASCS(EMS) WERE CHARACTERIZED BY INCREASED PROLIFERATION RATE, DECREASED APOPTOSIS AND SENESCENCE AND LOWER ROS ACCUMULATION. OUR FINDINGS OFFER A NOVEL APPROACH AND POTENTIAL TARGETS FOR THE BENEFICIAL EFFECTS OF AZA/RES IN AMELIORATING STEM CELL DYSFUNCTIONS. 2019 12 100 24 A QUINAZOLINE-BASED HDAC INHIBITOR AFFECTS GENE EXPRESSION PATHWAYS INVOLVED IN CHOLESTEROL BIOSYNTHESIS AND MEVALONATE IN PROSTATE CANCER CELLS. CHRONIC INFLAMMATION CAN LEAD TO THE DEVELOPMENT OF CANCERS AND RESOLUTION OF INFLAMMATION IS AN ONGOING CHALLENGE. INFLAMMATION CAN RESULT FROM DYSREGULATION OF THE EPIGENOME AND A NUMBER OF COMPOUNDS THAT MODIFY THE EPIGENOME ARE IN CLINICAL USE. IN THIS STUDY THE ANTI-INFLAMMATORY AND ANTI-CANCER EFFECTS OF A QUINAZOLINE EPIGENETIC-MODULATOR COMPOUND WERE DETERMINED IN PROSTATE CANCER CELL LINES USING A NON-HYPOTHESIS DRIVEN TRANSCRIPTOMICS STRATEGY UTILISING THE AFFYMETRIX PRIMEVIEW(R) HUMAN GENE EXPRESSION MICROARRAY. GATHER AND IPA SOFTWARE WERE USED TO ANALYSE THE DATA AND TO PROVIDE INFORMATION ON SIGNIFICANTLY MODIFIED BIOLOGICAL PROCESSES, PATHWAYS AND NETWORKS. A NUMBER OF GENES WERE DIFFERENTIALLY EXPRESSED IN BOTH PC3 AND DU145 PROSTATE CANCER CELL LINES. THE TOP CANONICAL PATHWAYS THAT FREQUENTLY AROSE ACROSS BOTH CELL LINES AT A NUMBER OF TIME POINTS INCLUDED CHOLESTEROL BIOSYNTHESIS AND METABOLISM, AND THE MEVALONATE PATHWAY. TARGETING OF STEROL AND MEVALONATE PATHWAYS MAY BE A POWERFUL ANTICANCER APPROACH. 2016 13 1902 33 ENHANCED EXPRESSION OF THE NUCLEAR ENVELOPE LAP2 TRANSCRIPTIONAL REPRESSORS IN NORMAL AND MALIGNANT ACTIVATED LYMPHOCYTES. EXTENSIVE RESEARCH IN RECENT YEARS HAS BROADENED THE FUNCTIONS OF NUCLEAR ENVELOPE PROTEINS BEYOND SIMPLY STABILIZING THE NUCLEUS ARCHITECTURE. PARTICULARLY, INTEGRAL NUCLEAR MEMBRANE PROTEINS, SUCH AS THE ALTERNATIVE SPLICED ISOFORMS OF LAMINA-ASSOCIATED POLYPEPTIDE 2 (LAP2), HAVE BEEN SHOWN TO BE IMPORTANT FOR THE INITIATION OF REPLICATION AND REPRESSION OF TRANSCRIPTION. THE LATTER IS REGULATED BY EPIGENETIC CHANGES, INDUCED BY THE BINDING OF LAP2BETA TO HISTONE DEACETYLASE-3 (HDAC3), RESULTING IN HISTONE H4 DEACETYLATION. INVOLVEMENT OF NUCLEAR ENVELOPE PROTEINS IN PATHOLOGICAL PROLIFERATIVE CONDITIONS, MAINLY THOSE INVOLVING ABNORMAL RECRUITMENT AND ACTIVATION OF HDACS, IS STILL UNKNOWN. IN THIS PAPER, WE SHOW THAT VARIOUS NUCLEAR ENVELOPE PROTEINS ARE HIGHLY EXPRESSED IN NORMAL AND MALIGNANT ACTIVATED LYMPHOCYTES. SPECIFICALLY, RAPIDLY REPLICATING CELLS OF VARIOUS HEMATOLOGICAL MALIGNANCIES HIGHLY EXPRESS LAP2BETA, WHILE SLOWLY PROLIFERATING MALIGNANT CELLS OF CHRONIC MALIGNANT HEMATOLOGICAL DISEASES DO NOT. TAKING TOGETHER THE ELEVATED EXPRESSION OF LAP2BETA IN HIGHLY PROLIFERATIVE MALIGNANT CELLS WITH ITS KNOWN ABILITY TO MODIFY HISTONES THROUGH BINDING WITH HDAC3 RAISES THE POSSIBILITY OF ITS ROLE IN HEMATOLOGICAL MALIGNANCIES INVOLVING ABERRANT ACTIVITY OF HDAC3. BASED ON OUR PRESENTED RESULTS, WE BELIEVE THAT THE LAP2-HDAC REGULATORY PATHWAY SHOULD BE STUDIED AS A NEW TARGET FOR RATIONAL THERAPY. 2007 14 2025 30 EPIGENETIC CHANGES DURING DISEASE PROGRESSION IN A MURINE MODEL OF HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA. EPIGENETIC ALTERATIONS, INCLUDING GAIN OR LOSS OF DNA METHYLATION, ARE A HALLMARK OF NEARLY EVERY MALIGNANCY. CHANGES IN DNA METHYLATION CAN IMPACT EXPRESSION OF CANCER-RELATED GENES INCLUDING APOPTOSIS REGULATORS AND TUMOR SUPPRESSORS. BECAUSE SUCH EPIGENETIC CHANGES ARE REVERSIBLE, THEY ARE BEING AGGRESSIVELY INVESTIGATED AS POTENTIAL THERAPEUTIC TARGETS. HERE WE USE THE EMU-TCL1 TRANSGENIC MOUSE MODEL OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TO DETERMINE THE TIMING AND PATTERNS OF ABERRANT DNA METHYLATION, AND TO INVESTIGATE THE MECHANISMS THAT LEAD TO ABERRANT DNA METHYLATION. WE SHOW THAT CLL CELLS FROM EMU-TCL1 MICE AT VARIOUS STAGES RECAPITULATE EPIGENETIC ALTERATIONS SEEN IN HUMAN CLL. ABERRANT METHYLATION OF PROMOTER SEQUENCES IS OBSERVED AS EARLY AS 3 MONTHS OF AGE IN THESE ANIMALS, WELL BEFORE DISEASE ONSET. ABNORMALLY METHYLATED PROMOTER REGIONS INCLUDE BINDING SITES FOR THE TRANSCRIPTION FACTOR FOXD3. WE SHOW THAT LOSS OF FOXD3 EXPRESSION DUE TO AN NF-KAPPAB P50/P50:HDAC1 REPRESSOR COMPLEX OCCURS IN TCL1-POSITIVE B CELLS BEFORE METHYLATION. THEREFORE, SPECIFIC TRANSCRIPTIONAL REPRESSION IS AN EARLY EVENT LEADING TO EPIGENETIC SILENCING OF TARGET GENES IN MURINE AND HUMAN CLL. THESE RESULTS PROVIDE STRONG RATIONALE FOR THE DEVELOPMENT OF STRATEGIES TO TARGET NF-KAPPAB COMPONENTS IN CLL AND POTENTIALLY OTHER B-CELL MALIGNANCIES. 2009 15 2926 31 GENERATION OF AN EPIGENETIC SIGNATURE BY CHRONIC HYPOXIA IN PROSTATE CELLS. INCREASING LEVELS OF TISSUE HYPOXIA HAVE BEEN REPORTED AS A NATURAL FEATURE OF THE AGING PROSTATE GLAND AND MAY BE A RISK FACTOR FOR THE DEVELOPMENT OF PROSTATE CANCER. IN THIS STUDY, WE HAVE USED PWR-1E BENIGN PROSTATE EPITHELIAL CELLS AND AN EQUIVALENTLY AGED HYPOXIA-ADAPTED PWR-1E SUB-LINE TO IDENTIFY PHENOTYPIC AND EPIGENETIC CONSEQUENCES OF CHRONIC HYPOXIA IN PROSTATE CELLS. WE HAVE IDENTIFIED A SIGNIFICANTLY ALTERED CELLULAR PHENOTYPE IN RESPONSE TO CHRONIC HYPOXIA AS CHARACTERIZED BY INCREASED RECEPTOR-MEDIATED APOPTOTIC RESISTANCE, THE INDUCTION OF CELLULAR SENESCENCE, INCREASED INVASION AND THE INCREASED SECRETION OF IL-1 BETA, IL6, IL8 AND TNFALPHA CYTOKINES. IN ASSOCIATION WITH THESE PHENOTYPIC CHANGES AND THE ABSENCE OF HIF-1 ALPHA PROTEIN EXPRESSION, WE HAVE DEMONSTRATED SIGNIFICANT INCREASES IN GLOBAL LEVELS OF DNA METHYLATION AND H3K9 HISTONE ACETYLATION IN THESE CELLS, CONCOMITANT WITH THE INCREASED EXPRESSION OF DNA METHYLTRANSFERASE DMNT3B AND GENE-SPECIFIC CHANGES IN DNA METHYLATION AT KEY IMPRINTING LOCI. IN CONCLUSION, WE HAVE DEMONSTRATED A GENOME-WIDE ADJUSTMENT OF DNA METHYLATION AND HISTONE ACETYLATION UNDER CHRONIC HYPOXIC CONDITIONS IN THE PROSTATE. THESE EPIGENETIC SIGNATURES MAY REPRESENT AN ADDITIONAL MECHANISM TO PROMOTE AND MAINTAIN A HYPOXIC-ADAPTED CELLULAR PHENOTYPE WITH A POTENTIAL ROLE IN TUMOUR DEVELOPMENT. 2009 16 3317 32 HISTOLOGICAL TRANSFORMATION TO SIGNET-RING CELL CARCINOMA IN A PATIENT WITH CLINICALLY AGGRESSIVE POORLY DIFFERENTIATED ADENOCARCINOMA OF THE ASCENDING COLON AFTER RESPONSE TO CHEMOTHERAPY PLUS CETUXIMAB: A CASE REPORT. BACKGROUND: ALTERATION OF CHEMOSENSITIVITY OR TUMOR AGGRESSIVENESS IN RESPONSE TO CHEMOTHERAPY HAS BEEN REPORTED, AND LIQUID BIOPSY ASSESSMENT DURING CHEMOTHERAPY FOR COLORECTAL CANCERS HAS CONFIRMED THE ACQUISITION OF MUTATIONS IN VARIOUS ONCOGENES. HOWEVER, THE OCCURRENCE OF HISTOLOGICAL TRANSFORMATION SEEMS TO BE EXTREMELY RARE IN COLORECTAL CANCERS, AND THE FEW EXISTING CASE REPORTS OF THIS TRANSFORMATION ARE FROM LUNG CANCER AND BREAST CANCER. IN THIS REPORT, WE DESCRIBE THE HISTOLOGICAL TRANSFORMATION OF CLINICALLY AGGRESSIVE SCIRRHOUS-TYPE POORLY DIFFERENTIATED ADENOCARCINOMA OF THE ASCENDING COLON TO SIGNET-RING CELL CARCINOMA IN ALMOST ALL RECURRENT TUMORS THAT WERE CONFIRMED BY AUTOPSY AFTER RESPONSE TO CHEMOTHERAPY PLUS CETUXIMAB. CASE PRESENTATION: A 59-YEAR-OLD WOMAN VISITED OUR HOSPITAL WITH WHOLE ABDOMINAL PAIN AND BODY WEIGHT LOSS AND WAS DIAGNOSED WITH SCIRRHOUS-TYPE POORLY DIFFERENTIATED ADENOCARCINOMA OF THE ASCENDING COLON WITH AGGRESSIVE LYMPH NODE METASTASES. THE INTRINSIC CHEMOSENSITIVITY OF THE TUMORS WAS EVIDENT UPON INITIATION OF MFOLFOX6 PLUS CETUXIMAB THERAPY, AND RIGHT HEMICOLECTOMY WAS PERFORMED, AND THE TUMOR OBVIOUSLY REMAINED IN THE PERIPANCREATIC AREA, PARAAORTIC REGION, OR OTHER RETROPERITONEAL AREAS. THE ASCENDING COLON TUMORS MAINLY CONSISTED OF POORLY DIFFERENTIATED ADENOCARCINOMA AND WERE NOT ASSOCIATED WITH SIGNET-RING CELL COMPONENTS EXCEPT FOR MINUTE CLUSTERS IN A FEW LYMPHATIC EMBOLI IN THE MAIN TUMOR. CHEMOTHERAPY WAS CONTINUED, AND METASTASES WERE ELIMINATED AT 8 MONTHS AFTER THE OPERATION; THIS RESPONSE WAS MAINTAINED FOR AN ADDITIONAL 4 MONTHS. DISCONTINUATION OF CHEMOTHERAPY PLUS CETUXIMAB RESULTED IN IMMEDIATE TUMOR RECURRENCE AND RAPID EXPANSION, AND THE PATIENT DIED OF THE RECURRENT TUMOR 1 YEAR AND 2 MONTHS AFTER THE OPERATION. AUTOPSY SPECIMENS REVEALED THAT ALMOST ALL OF THE RECURRENT TUMORS EXHIBITED TRANSFORMATION AND CONSISTED OF SIGNET-RING CELL HISTOLOGY. CONCLUSION: THIS CASE MIGHT SUGGEST THAT VARIOUS ONCOGENE MUTATIONS OR EPIGENETIC CHANGES RESULTING FROM CHEMOTHERAPY, ESPECIALLY REGIMENS THAT INCLUDE CETUXIMAB, CONTRIBUTE TO THE TRANSFORMATION OF NON-SIGNET-RING CELL COLORECTAL CARCINOMA TO SIGNET-RING CELL CARCINOMA HISTOLOGY AND CAN PROMOTE THE AGGRESSIVE CLINICAL PROGRESSION CHARACTERISTIC OF SIGNET-RING CELL CARCINOMA. 2023 17 3823 35 INVESTIGATING THE EFFECTS OF A SYNTHETIC CANNABINOID ON THE PATHOGENESIS OF LEUKEMIA AND LEUKEMIC STEM CELLS: A NEW THERAPEUTIC APPROACH. THE POPULARITY AND USAGE OF SYNTHETIC CANNABINOIDS (SCS) ARE INCREASING DUE TO THEIR EASY ACCESSIBILITY AND PSYCHOACTIVE EFFECTS WORLDWIDE. STUDIES ON CANNABINOIDS ON LEUKEMIC STEM CELLS (LSC) AND HEMATOPOIETIC STEM CELLS (HSCS), WHICH ARE THE PRECURSORS OF LEUKEMIA CELLS, GENERALLY DEPEND ON THE NATURAL CANNABINOID DELTA-9-THC. AS THERE IS ONLY A LIMITED NUMBER OF STUDIES FOCUSING ON THE RESULTS OF SC APPLICATIONS, THE REFLECTIONS UPON LSCS HAVE TO BE CLARIFIED. IN THIS STUDY, BIOLOGICAL RESPONSES AND ANTILEUKEMIC EFFECTS OF JWH-018-ONE OF THE FIRST PRODUCED AND WIDELY USED SCS-WERE EVALUATED UPON LEUKEMIA CELLS. WHETHER JWH-018 EXHIBITED A PREVENTIVE EFFECT ON BOTH LEUKEMIC AND HSCS WAS EVALUATED BY PRESENTING A THERAPEUTIC APPROACH FOR THE FIRST TIME IN THE LITERATURE. CELLS WERE ANALYZED IN CASE OF CELL PROLIFERATION, APOPTOSIS, AND TRANSCRIPTIONAL EXPRESSION PROFILING OF SOME SIGNIFICANT JAK/STAT AND AKT/MTOR PATHWAYS, APOPTOTIC, CELL CYCLE REGULATION, AND EPIGENETIC CHROMATIN REMODELING-RELATED GENES FOLLOWING JWH-018 TREATMENT. IN CONCLUSION, HOWEVER, FURTHER STUDIES ARE STILL NEEDED UPON BOTH HSCS AND LSCS TO ILLUMINATE THE EFFECTS OF SCS ON LEUKEMOGENESIS ON CHRONIC MYELOID LEUKEMIA (CML) MORE CLEARLY; WE CONSIDER THAT THE JWH-018 CAN PROVIDE A THERAPEUTIC EFFECT ON THE PATHOGENESIS OF LEUKEMIA AND PARTICULARLY UPON LSCS AND SCS MIGHT HAVE THERAPEUTIC POTENTIAL IN ADDITION TO CURRENT THERAPY. 2022 18 3525 30 IL-1BETA, IL-8, AND MATRIX METALLOPROTEINASES-1, -2, AND -10 ARE ENRICHED UPON MONOCYTE-BREAST CANCER CELL COCULTIVATION IN A MATRIGEL-BASED THREE-DIMENSIONAL SYSTEM. BREAST CANCER REMAINS THE FIRST CANCER-RELATED CAUSE OF DEATH IN WOMEN WORLDWIDE, PARTICULARLY IN DEVELOPING COUNTRIES IN WHICH MOST CASES ARE DIAGNOSED IN LATE STAGES. ALTHOUGH MOST CANCER STUDIES ARE BASED IN THE GENETIC OR EPIGENETIC CHANGES OF THE TUMOR CELLS, IMMUNE CELLS WITHIN THE TUMOR STROMA OFTEN COOPERATE WITH CANCER PROGRESSION. PARTICULARLY, MONOCYTES ARE ATTRACTED TO THE TUMOR PRIMARY SITE IN WHICH THEY ARE DIFFERENTIATED INTO TUMOR-ASSOCIATED MACROPHAGES THAT FACILITATE TUMOR CELL INVASION AND METASTASIS. IN THIS STUDY, WE USED THREE-DIMENSIONAL CULTURES TO FORM ACINI-LIKE STRUCTURES TO ANALYZE THE INFLAMMATORY SECRETION PROFILE OF TUMOR CELLS INDIVIDUALLY OR IN CO-CULTURE WITH MONOCYTES. BREAST CANCER CELL LINES AND PRIMARY ISOLATES FROM EIGHT MEXICAN PATIENTS WITH BREAST CANCER WERE USED. WE FOUND HIGH LEVELS OF RANTES/CCL5, MCP-1/CCL2, AND G-CSF IN THE BREAST CANCER INDIVIDUAL CULTURES, SUPPORTING AN IMPORTANT RECRUITMENT CAPACITY OF MONOCYTES, BUT ALSO OF NEUTROPHILS. THE CO-CULTURES OF THE TUMOR CELLS AND MONOCYTES WERE SIGNIFICANTLY ENRICHED WITH THE POTENT PRO-INFLAMMATORY CYTOKINES INTERLEUKIN (IL)-1BETA AND IL-8, KNOWN TO SUPPORT MALIGNANT PROGRESSION. WE ALSO FOUND THAT THE INTERACTION OF TUMOR CELLS WITH MONOCYTES PROMOTED HIGH LEVELS OF MATRIX METALLOPROTEINASES (MMP)-1, MMP-2, AND MMP-10. OUR STUDY SUPPORTS THAT A KEY EVENT FOR MALIGNANT PROGRESSION IS THE RECRUITMENT OF DIFFERENT IMMUNE CELL POPULATIONS, WHICH HELP TO SUSTAIN AND ENHANCE A CHRONIC INFLAMMATORY MICROENVIRONMENT THAT HIGHLY FAVORS TUMOR MALIGNANCY. 2017 19 5688 32 SILENCING EFFECTS OF MUTANT RAS SIGNALLING ON TRANSCRIPTOMES. MUTATED GENES OF THE RAS FAMILY ENCODING SMALL GTP-BINDING PROTEINS DRIVE NUMEROUS CANCERS, INCLUDING PANCREATIC, COLON AND LUNG TUMORS. BESIDES THE NUMEROUS EFFECTS OF MUTANT RAS GENE EXPRESSION ON ABERRANT PROLIFERATION, TRANSFORMED PHENOTYPES, METABOLISM, AND THERAPY RESISTANCE, THE MOST STRIKING CONSEQUENCES OF CHRONIC RAS ACTIVATION ARE CHANGES OF THE GENETIC PROGRAM. BY PERFORMING SYSTEMATIC GENE EXPRESSION STUDIES IN CELLULAR MODELS THAT ALLOW COMPARISONS OF PRE-NEOPLASTIC WITH RAS-TRANSFORMED CELLS, WE AND OTHERS HAVE ESTIMATED THAT 7 PERCENT OR MORE OF ALL TRANSCRIPTS ARE ALTERED IN CONJUNCTION WITH THE EXPRESSION OF THE ONCOGENE. IN THIS CONTEXT, THE NUMBER OF UP-REGULATED TRANSCRIPTS APPROXIMATES THAT OF DOWN-REGULATED TRANSCRIPTS. WHILE UP-REGULATED TRANSCRIPTION FACTORS SUCH AS MYC, FOSL1, AND HMGA2 HAVE BEEN IDENTIFIED AND CHARACTERIZED AS RAS-RESPONSIVE DRIVERS OF THE ALTERED TRANSCRIPTOME, THE SUPPRESSED FACTORS HAVE BEEN LESS WELL STUDIED AS POTENTIAL REGULATORS OF THE GENETIC PROGRAM AND TRANSFORMED PHENOTYPE IN THE BREADTH OF THEIR OCCURRENCE. WE THEREFORE HAVE COLLECTED INFORMATION ON DOWNREGULATED RAS-RESPONSIVE FACTORS AND DISCUSS THEIR POTENTIAL ROLE AS TUMOR SUPPRESSORS THAT ARE LIKELY TO ANTAGONIZE ACTIVE CANCER DRIVERS. TO BETTER UNDERSTAND THE ACTIVE MECHANISMS THAT ENTAIL ANTI-RAS FUNCTION AND THOSE THAT LEAD TO LOSS OF TUMOR SUPPRESSOR ACTIVITY, WE FOCUS ON THE TUMOR SUPPRESSOR HREV107 (ALIAS PLAAT3 [PHOSPHOLIPASE A AND ACYLTRANSFERASE 3], PLA2G16 [PHOSPHOLIPASE A2, GROUP XVI] AND HRASLS3 [HRAS-LIKE SUPPRESSOR 3]). INACTIVATING HREV107 MUTATIONS IN TUMORS ARE EXTREMELY RARE, HENCE EPIGENETIC CAUSES MODULATED BY THE RAS PATHWAY ARE LIKELY TO LEAD TO DOWN-REGULATION AND LOSS OF FUNCTION. 2023 20 6421 41 THE THERAPEUTIC PROPERTIES OF RESMINOSTAT FOR HEPATOCELLULAR CARCINOMA. HEPATOCELLULAR CARCINOMA (HCC) IS THE MOST COMMON FORM OF PRIMARY LIVER CANCER WITH INCREASES IN NEW CASES BEING REPORTED ANNUALLY. HISTOPATHOLOGISTS HAVE IDENTIFIED HEPATIC STEATOSIS AS A CHARACTERISTIC OF A BROAD RANGE OF CHRONIC LIVER DISEASES THAT ARE ASSOCIATED WITH THE ONSET AND DEVELOPMENT OF HCC. IN THIS CONTEXT, EPIGENETIC MODIFICATIONS MAY SERVE AS PRECANCEROUS FACTORS PREDISPOSING NORMAL CELLS TO THE INITIATION OF CARCINOGENESIS. THIS STUDY DEMONSTRATED THAT HEPATIC TUMORIGENESIS AND DIFFERENTIATED ADIPOCYTES MAY MODULATE BOTH GLOBAL HISTONE DEACETYLASE (HDAC) EXPRESSION AND SPECIFIC CLASS I HDAC GENES IN THE TUMOUR MICROENVIRONMENT. THE NOVEL CLASS I HDAC INHIBITOR RESMINOSTAT WAS SHOWN TO REDUCE THE PROLIFERATION OF HCC CELLS ALONG WITH ITS SPECIFICITY IN TARGETING CLASS I HDACS AND ONCOGENES. THE COMBINED EFFECT OF RESMINOSTAT WITH SEVERAL PHARMACEUTICAL AGENTS SUCH AS SORAFENIB, CISPLATIN AND DOXORUBICIN WAS ALSO DEMONSTRATED. THE INHIBITION OF HEAT SHOCK PROTEIN 90 (HSP90) HAS BEEN DEMONSTRATED AS A POTENTIAL THERAPEUTIC OPTION FOR HCC. IN LINE WITH THIS, THE SPECIFIC HSP90 INHIBITOR 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN (17-AAG) WAS SELECTED AND IT WAS FOUND THAT THE COMBINATION OF RESMINOSTAT AND 17-AAG MAY PROVIDE A "SMART" CLINICAL STRATEGY FOR HCC PATIENTS BY TARGETING CELLULAR COMMUNICATION WITHIN THE TUMOUR MICROENVIRONMENT. THIS STUDY PROVIDES AN INSIGHT INTO THE USE OF RESMINOSTAT AS AN EPIGENETIC BASED THERAPEUTIC FOR HCC ALONG WITH OTHER PHARMACEUTICAL OPTIONS, IN PARTICULAR BY TARGETING THE CELL-TO-CELL COMMUNICATION THAT OCCURS BETWEEN HEPATOMA AND ADIPOCYTES. 2018